Transition in 2019
25/03/19 -"We have factored in our slightly more cautious view as we assume the investments for future growth in 2019 and the quick change at the CEO level will have some adverse effects on the company. Despite ..."
Pages
66
Language
English
Published on
25/03/19
You may also be interested by these reports :
17/04/24
Q1 sales exceeded expectations, driven by a strong performance from the Companion Animal segment. The Farm Animal segment was however held back by a ...
16/04/24
Preview: Positive 1Q24 driven by clinical developments of portfolio companies
15/04/24
Investor appetite for Merck KGaA (Add, Germany) shares has been somewhat subdued since we last teased the name (15/03/2021). At that time, the ...
15/04/24
Turnaround story on track – TP increased to CHF 30.00 (from CHF 25.00) – Add reiterated